Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 7/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24589285 | 0.83 | PIN1 (0.37) | PIN1ALDH1A1HSP90AA1ESR2TDP1 | |
| SCHEMBL27882640 | 0.79 | PIN1 (0.52) | PIN1HCAR2ALDH1A1KDM4EPKM | |
| SCHEMBL27571567 | 0.79 | PIN1 (0.39) | PIN1HCAR2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL213561 | 0.79 | PIN1 (0.48) | PIN1HCAR2ALDH1A1KDM4EHSP90AA1 | |
| SCHEMBL1079177 | 0.79 | PARP1 (0.41) | PIN1ALDH1A1MAPK1MAPT | |
| SCHEMBL9232538 | 0.77 | PIN1 (0.50) | PIN1HCAR2ALDH1A1KDM4EPKM | |
| SCHEMBL5433660 | 0.77 | PIN1 (0.38) | PIN1HCAR2ALDH1A1HSP90AA1ESR2 | |
| SCHEMBL5303269 | 0.77 | PIN1 (0.50) | PIN1HCAR2ALDH1A1KDM4EPKM | |
| SCHEMBL1078582 | 0.76 | PIN1 (0.39) | PIN1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19077882 | 0.74 | PIN1 (0.47) | PIN1HCAR2ALDH1A1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3277678-B1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | NANTBIO, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-09 | — | — | US | disclosed |
| US-5691366-A | UNSATURATED NITRO OXIME FORMED BY REACTION OF DINITROGEN TRIOXIDE WITH DIOLEFIN ETHER, SULFIDE OR AMINE TO BE USED AS VASODILATORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-25 | — | — | US | disclosed |
| US-5495023-A | VASODILATORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-27 | — | — | US | disclosed |
| EP-0612315-A1 | NITRO COMPOUNDS HAVING VASODILATOR ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
| WO-1993010097-A1 | NITRO COMPOUNDS HAVING VASODILATOR ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-27 | — | — | WO | disclosed |
| US-4672128-A | REACTING IMIDAZOLES WITH CARBON DIOXIDE AND AN ALKALI METAL CARBONATE, BICARBONATE, OR HYDROXIDE AT ELEVATED TEMPERATURE AND PRESSURE | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-09 | — | — | US | disclosed |
| EP-0172407-A1 | Process for the preparation of imidazole-4(5)-monocarbonic acids, their salts or betains | BASF Aktiengesellschaft (DE) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | PIN1 3380/4885HCAR2 3931/4885ALDH1A1 4260/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | PIN1 3380/4885HCAR2 3931/4885ALDH1A1 4260/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | PIN1 3380/4885HCAR2 3931/4885ALDH1A1 4260/4885 |
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | KRAS, NRAS, HRAS | PIN1 2459/4885HCAR2 4303/4885ALDH1A1 4472/4885 |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | KRAS, NRAS, HRAS | PIN1 2459/4885HCAR2 4303/4885ALDH1A1 4472/4885 |
| US-20120032121-A1 | METALLIC COMPOSITE AND COMPOSITION THEREOF | CDH1, EPCAM, CD4 | PIN1 536/4885HCAR2 4855/4885ALDH1A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.